Keywords
Last Name

David H. Sherr, PhD

TitleProfessor
InstitutionBoston University School of Public Health
DepartmentEnvironmental Health
Address72 E. Concord St Housman (R)
Boston MA 02118
Phone(617) 638-6464
ORCID ORCID Icon0000-0003-3353-0553
Other Positions
TitleGraduate Faculty (Primary Mentor of Grad Students)
InstitutionBoston University School of Medicine, Division of Graduate Medical Sciences

TitleProfessor
InstitutionBoston University School of Medicine
DepartmentPathology & Laboratory Medicine

TitleDirector
InstitutionBoston University
DepartmentSuperfund Research Program

TitleDirector
InstitutionBoston University
DepartmentImmunology Training Program

 Awards and Honors

Start-EndDescription
2014-2016Avon Foundation: Research Award
 Research Expertise & Professional Interests
Since 1993, David Sherr's laboratory has conducted research on how common environmental pollutants, such as dioxins, polycyclic aromatic hydrocarbons and PCBs, adversely affect the growth and behavior of several different types of normal and malignant cells. In previous work, the Sherr laboratory studied how environmental chemicals affect the development of the immune system. In specific, his laboratory demonstrated that aromatic hydrocarbons (generated by the combuston of any carbon source) compromise the function of bone marrow cells required for the development of antibody-forming cells. These cells are critical for immune protection against viruses and bacteria. This work had its orignis in Dr. Sherr's graduate studies on the ontogeny of lymphocyte development.

More recently, Dr. Sherr's laboratory has focused on the molecular mechanisms that initiate and maintain breast cancer and on the effects of environmental chemicals on these processes. The laboratory has shown that a cellular protein receptor, referred to as the aryl hydrocarbon receptor (AhR), plays an important role in the initiation and progression of human breast cancer. The results explain, in part, the association between environmental chemical exposure and breast cancer risk. Perhaps most importantly, these studies demonstrate that the AhR drives human breast cancer cells to invade and, presumably, metastasize even in the absence of environmental chemicals. These observations have led to the development of AhR inhibitors which block AhR activity and prevent tumor cells from invading. One immediate goal of the laboratory, therefore, is the development of potent AhR inhibitors as novel, targeted therapeutics to be used for treatment of all breast cancers but especially for treatment of "triple negative" or chemotherapy-resistant breast cancers. Interestingly, preliminary studies suggest that these AhR inhibitors could be useful for treatment of several other cancer cell types.

A new area of study in Dr. Sherr's laboratory is the analysis of the role of the AhR in blood cell development. These studies are important from both an environmental science and medical science point of view. Studies performed to date suggest that the AhR plays an important roll in the normal development of blood cells. The results suggest the intriguing possibility that common environmental pollutants can alter normal blood cell development by interfering with AhR signaling.

Dr. Sherr came to BUSPH from the faculty of Harvard Medical School, where he had earlier been a postdoctoral fellow in the department of Nobel Laureate Baruj Benacerraf. The Sherr Laboratory is funded by research grants from the National Institute of Environmental Health Sciences, the NIH Superfund Basic Research Program, and the Art BeCAUSE breast cancer foundation. Dr. Sherr is the Director of the Boston University Immunology Training Program, and a member of the Amyloid Treatment Research Program, the BU Cancer Center, the Hematology/Oncology Training Program, and the BU Hormone-dependent Cancer Center. He has trained 21 postdoctoral (M.D. or Ph.D.) and 11 predoctoral (M.D. and/or Ph.D.) fellows.

 Self-Described Keywords
  • Aryl hydrocarbon receptor
  • Breast cancer and the environment
  • Immunology
  • Toxicology
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Mulas F, Li A, Sherr DH, Monti S. Network-based analysis of transcriptional profiles from chemical perturbations experiments. BMC Bioinformatics. 2017 Mar 23; 18(Suppl 5):130. PMID: 28361664.
    View in: PubMed
  2. Novikov O, Wang Z, Stanford EA, Parks AJ, Ramirez-Cardenas A, Landesman E, Laklouk I, Sarita-Reyes C, Gusenleitner D, Li A, Monti S, Manteiga S, Lee K, Sherr DH. An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells. Mol Pharmacol. 2016 Nov; 90(5):674-688. PMID: 27573671.
    View in: PubMed
  3. Chen HR, Sherr DH, Hu Z, DeLisi C. A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer. BMC Med Genomics. 2016 Jul 30; 9(1):51. PMID: 27475327.
    View in: PubMed
  4. Stanford EA, Ramirez-Cardenas A, Wang Z, Novikov O, Alamoud K, Koutrakis P, Mizgerd JP, Genco CA, Kukuruzinska M, Monti S, Bais MV, Sherr DH. Role for the Aryl Hydrocarbon Receptor and Diverse Ligands in Oral Squamous Cell Carcinoma Migration and Tumorigenesis. Mol Cancer Res. 2016 Aug; 14(8):696-706. PMID: 27130942.
    View in: PubMed
  5. Smith BW, Stanford EA, Sherr DH, Murphy GJ. Genome Editing of the CYP1A1 Locus in iPSCs as a Platform to Map AHR Expression throughout Human Development. Stem Cells Int. 2016; 2016:2574152. PMID: 27148368.
    View in: PubMed
  6. Stanford EA, Wang Z, Novikov O, Mulas F, Landesman-Bollag E, Monti S, Smith BW, Seldin DC, Murphy GJ, Sherr DH. The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells. BMC Biol. 2016 Mar 16; 14:20. PMID: 26984638.
    View in: PubMed
  7. Grandjean P, Barouki R, Bellinger DC, Casteleyn L, Chadwick LH, Cordier S, Etzel RA, Gray KA, Ha EH, Junien C, Karagas M, Kawamoto T, Paige Lawrence B, Perera FP, Prins GS, Puga A, Rosenfeld CS, Sherr DH, Sly PD, Suk W, Sun Q, Toppari J, van den Hazel P, Walker CL, Heindel JJ. Life-Long Implications of Developmental Exposure to Environmental Stressors: New Perspectives. Endocrinology. 2015 Oct; 156(10):3408-15. PMID: 26241067.
    View in: PubMed
  8. Shivanna S, Kolandaivelu K, Shashar M, Belghasim M, Al-Rabadi L, Balcells M, Zhang A, Weinberg J, Francis J, Pollastri MP, Edelman ER, Sherr DH, Chitalia VC. The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia. J Am Soc Nephrol. 2016 Jan; 27(1):189-201. PMID: 26019318.
    View in: PubMed
  9. Parks AJ, Pollastri MP, Hahn ME, Stanford EA, Novikov O, Franks DG, Haigh SE, Narasimhan S, Ashton TD, Hopper TG, Kozakov D, Beglov D, Vajda S, Schlezinger JJ, Sherr DH. In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol. 2014 Nov; 86(5):593-608. PMID: 25159092.
    View in: PubMed
  10. Gusenleitner D, Auerbach SS, Melia T, Gómez HF, Sherr DH, Monti S. Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of action. PLoS One. 2014; 9(7):e102579. PMID: 25058030.
    View in: PubMed
  11. Lowe MM, Mold JE, Kanwar B, Huang Y, Louie A, Pollastri MP, Wang C, Patel G, Franks DG, Schlezinger J, Sherr DH, Silverstone AE, Hahn ME, McCune JM. Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production. PLoS One. 2014; 9(2):e87877. PMID: 24498387.
    View in: PubMed
  12. Gusenleitner, D., S. Auerbach, H. Gomez, T. Meila, R. Tice, D. Sherr, and S. Monti. Genomics Model of Environmental and Chemical Hepatocarcinogenicity. PLOS One. 2014.
  13. Sherr DH, Monti S. The role of the aryl hydrocarbon receptor in normal and malignant B cell development. Semin Immunopathol. 2013 Nov; 35(6):705-16. PMID: 23942720.
    View in: PubMed
  14. Sherr DH. Blocking triple negative breast cancer. International Innovations. 2013.
  15. Quintana FJ, Sherr DH. Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol Rev. 2013; 65(4):1148-61. PMID: 23908379.
    View in: PubMed
  16. Smith BW, Rozelle SS, Leung A, Ubellacker J, Parks A, Nah SK, French D, Gadue P, Monti S, Chui DH, Steinberg MH, Frelinger AL, Michelson AD, Theberge R, McComb ME, Costello CE, Kotton DN, Mostoslavsky G, Sherr DH, Murphy GJ. The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. Blood. 2013 Jul 18; 122(3):376-85. PMID: 23723449.
    View in: PubMed
  17. Selmi C, Leung PS, Sherr DH, Diaz M, Nyland JF, Monestier M, Rose NR, Gershwin ME. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. J Autoimmun. 2012 Dec; 39(4):272-84. PMID: 22749494.
    View in: PubMed
  18. Lawrence BP, Sherr DH. You AhR what you eat? Nat Immunol. 2012 Feb; 13(2):117-9. PMID: 22261961.
    View in: PubMed
  19. Flies A, Ahmadi T, Parks AJ, Prokaeva T, Weng L, Rolfe SS, Seldin DC, Sherr DH. Immunoglobulin light chain, Blimp-1 and cytochrome P4501B1 peptides as potential vaccines for AL amyloidosis. Immunol Cell Biol. 2012 May; 90(5):528-39. PMID: 21894172.
    View in: PubMed
  20. Sherr DH. Another important biological function for the aryl hydrocarbon receptor. Arterioscler Thromb Vasc Biol. 2011 Jun; 31(6):1247-8. PMID: 21593454.
    View in: PubMed
  21. Ehrlich DJ, McKenna BK, Evans JG, Belkina AC, Denis GV, Sherr DH, Cheung MC. Parallel imaging microfluidic cytometer. Methods Cell Biol. 2011; 102:49-75. PMID: 21704835.
    View in: PubMed
  22. Teague JE, Ryu HY, Kirber M, Sherr DH, Schlezinger JJ. Proximal events in 7,12-dimethylbenz[a]anthracene-induced, stromal cell-dependent bone marrow B cell apoptosis: stromal cell-B cell communication and apoptosis signaling. J Immunol. 2010 Sep 15; 185(6):3369-78. PMID: 20720205.
    View in: PubMed
  23. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, Kuchroo VK. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol. 2010 Sep; 11(9):854-61. PMID: 20676095.
    View in: PubMed
  24. Schlezinger JJ, Bernard PL, Haas A, Grandjean P, Weihe P, Sherr DH. Direct assessment of cumulative aryl hydrocarbon receptor agonist activity in sera from experimentally exposed mice and environmentally exposed humans. Environ Health Perspect. 2010 May; 118(5):693-8. PMID: 20435556.
    View in: PubMed
  25. Allan LL, Sherr DH. Disruption of human plasma cell differentiation by an environmental polycyclic aromatic hydrocarbon: a mechanistic immunotoxicological study. Environ Health. 2010; 9:15. PMID: 20334656.
    View in: PubMed
  26. Karchner SI, Jenny MJ, Tarrant AM, Evans BR, Kang HJ, Bae I, Sherr DH, Hahn ME. The active form of human aryl hydrocarbon receptor (AHR) repressor lacks exon 8, and its Pro 185 and Ala 185 variants repress both AHR and hypoxia-inducible factor. Mol Cell Biol. 2009 Jul; 29(13):3465-77. PMID: 19380484.
    View in: PubMed
  27. Hahn ME, Allan LL, Sherr DH. Regulation of constitutive and inducible AHR signaling: complex interactions involving the AHR repressor. Biochem Pharmacol. 2009 Feb 15; 77(4):485-97. PMID: 18848529.
    View in: PubMed
  28. Bissonnette SL, Teague JE, Sherr DH, Schlezinger JJ. An endogenous prostaglandin enhances environmental phthalate-induced apoptosis in bone marrow B cells: activation of distinct but overlapping pathways. J Immunol. 2008 Aug 1; 181(3):1728-36. PMID: 18641309.
    View in: PubMed
  29. Min C, Eddy SF, Sherr DH, Sonenshein GE. NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem. 2008 Jun 1; 104(3):733-44. PMID: 18253935.
    View in: PubMed
  30. Yang X, Solomon S, Fraser LR, Trombino AF, Liu D, Sonenshein GE, Hestermann EV, Sherr DH. Constitutive regulation of CYP1B1 by the aryl hydrocarbon receptor (AhR) in pre-malignant and malignant mammary tissue. J Cell Biochem. 2008 May 15; 104(2):402-17. PMID: 18059014.
    View in: PubMed
  31. Belguise K, Guo S, Yang S, Rogers AE, Seldin DC, Sherr DH, Sonenshein GE. Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Res. 2007 Dec 15; 67(24):11742-50. PMID: 18089804.
    View in: PubMed
  32. Ahmadi T, Flies A, Efebera Y, Sherr DH. CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology. 2008 May; 124(1):129-40. PMID: 18067555.
    View in: PubMed
  33. Evans BR, Karchner SI, Allan LL, Pollenz RS, Tanguay RL, Jenny MJ, Sherr DH, Hahn ME. Repression of aryl hydrocarbon receptor (AHR) signaling by AHR repressor: role of DNA binding and competition for AHR nuclear translocator. Mol Pharmacol. 2008 Feb; 73(2):387-98. PMID: 18000031.
    View in: PubMed
  34. Schlezinger JJ, Emberley JK, Bissonnette SL, Sherr DH. An L-tyrosine derivative and PPARgamma agonist, GW7845, activates a multifaceted caspase cascade in bone marrow B cells. Toxicol Sci. 2007 Jul; 98(1):125-36. PMID: 17400580.
    View in: PubMed
  35. Schlezinger JJ, Liu D, Farago M, Seldin DC, Belguise K, Sonenshein GE, Sherr DH. A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biol Chem. 2006 Sep; 387(9):1175-87. PMID: 16972784.
    View in: PubMed
  36. Schlezinger JJ, Emberley JK, Sherr DH. Activation of multiple mitogen-activated protein kinases in pro/pre-B cells by GW7845, a peroxisome proliferator-activated receptor gamma agonist, and their contribution to GW7845-induced apoptosis. Toxicol Sci. 2006 Aug; 92(2):433-44. PMID: 16672323.
    View in: PubMed
  37. Murray TJ, Yang X, Sherr DH. Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A. Breast Cancer Res. 2006; 8(2):R17. PMID: 16569260.
    View in: PubMed
  38. Shin SR, Sánchez-Velar N, Sherr DH, Sonenshein GE. 7,12-dimethylbenz(a)anthracene treatment of a c-rel mouse mammary tumor cell line induces epithelial to mesenchymal transition via activation of nuclear factor-kappaB. Cancer Res. 2006 Mar 1; 66(5):2570-5. PMID: 16510574.
    View in: PubMed
  39. Allan LL, Schlezinger JJ, Shansab M, Sherr DH. CYP1A1 in polycyclic aromatic hydrocarbon-induced B lymphocyte growth suppression. Biochem Biophys Res Commun. 2006 Mar 31; 342(1):227-35. PMID: 16472762.
    View in: PubMed
  40. Yang X, Liu D, Murray TJ, Mitchell GC, Hesterman EV, Karchner SI, Merson RR, Hahn ME, Sherr DH. The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cells. Oncogene. 2005 Nov 24; 24(53):7869-81. PMID: 16091746.
    View in: PubMed
  41. Murray SA, Yang S, Demicco E, Ying H, Sherr DH, Hafer LJ, Rogers AE, Sonenshein GE, Xiao ZX. Increased expression of MDM2, cyclin D1, and p27Kip1 in carcinogen-induced rat mammary tumors. J Cell Biochem. 2005 Aug 1; 95(5):875-84. PMID: 15844214.
    View in: PubMed
  42. Ryu HY, Emberley JK, Schlezinger JJ, Allan LL, Na S, Sherr DH. Environmental chemical-induced bone marrow B cell apoptosis: death receptor-independent activation of a caspase-3 to caspase-8 pathway. Mol Pharmacol. 2005 Oct; 68(4):1087-96. PMID: 16014577.
    View in: PubMed
  43. Maecker B, von Bergwelt-Baildon MS, Sherr DH, Nadler LM, Schultze JL. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer. 2005 Jun 10; 115(2):333-6. PMID: 15688394.
    View in: PubMed
  44. Schaefer KL, Denevich S, Ma C, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D, Saubermann LJ. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis. 2005 Mar; 11(3):244-52. PMID: 15735430.
    View in: PubMed
  45. Allan LL, Sherr DH. Constitutive activation and environmental chemical induction of the aryl hydrocarbon receptor/transcription factor in activated human B lymphocytes. Mol Pharmacol. 2005 May; 67(5):1740-50. PMID: 15681594.
    View in: PubMed
  46. Currier N, Solomon SE, Demicco EG, Chang DL, Farago M, Ying H, Dominguez I, Sonenshein GE, Cardiff RD, Xiao ZX, Sherr DH, Seldin DC. Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol. 2005; 33(6):726-37. PMID: 16263698.
    View in: PubMed
  47. Schlezinger JJ, Howard GJ, Hurst CH, Emberley JK, Waxman DJ, Webster T, Sherr DH. Environmental and endogenous peroxisome proliferator-activated receptor gamma agonists induce bone marrow B cell growth arrest and apoptosis: interactions between mono(2-ethylhexyl)phthalate, 9-cis-retinoic acid, and 15-deoxy-Delta12,14-prostaglandin J2. J Immunol. 2004 Sep 1; 173(5):3165-77. PMID: 15322177.
    View in: PubMed
  48. Sherr DH. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and long term immunologic memory. Toxicol Sci. 2004 Jun; 79(2):211-3. PMID: 15185717.
    View in: PubMed
  49. Xiao S, Zhang X, Mann KK, Jodo S, Li L, Jarjour WN, Marshak-Rothstein A, Sherr DH, Ju ST. Changes in sensitivity of peripheral lymphocytes of autoimmune gld mice to FasL-mediated apoptosis reveal a mechanism for the preferential deletion of CD4-CD8-B220+ T cells. Int Immunol. 2004 May; 16(5):759-66. PMID: 15096479.
    View in: PubMed
  50. Jensen BA, Leeman RJ, Schlezinger JJ, Sherr DH. Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells: an immunotoxicology study. Environ Health. 2003 Dec 16; 2(1):16. PMID: 14678569.
    View in: PubMed
  51. Tiwari S, Felekkis K, Moon EY, Flies A, Sherr DH, Lerner A. Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis. Blood. 2004 Apr 1; 103(7):2661-7. PMID: 14615375.
    View in: PubMed
  52. Allan LL, Mann KK, Matulka RA, Ryu HY, Schlezinger JJ, Sherr DH. Bone marrow stromal-B cell interactions in polycyclic aromatic hydrocarbon-induced pro/pre-B cell apoptosis. Toxicol Sci. 2003 Dec; 76(2):357-65. PMID: 14514961.
    View in: PubMed
  53. Maecker B, Sherr DH, Vonderheide RH, von Bergwelt-Baildon MS, Hirano N, Anderson KS, Xia Z, Butler MO, Wucherpfennig KW, O'Hara C, Cole G, Kwak SS, Ramstedt U, Tomlinson AJ, Chicz RM, Nadler LM, Schultze JL. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood. 2003 Nov 1; 102(9):3287-94. PMID: 12869499.
    View in: PubMed
  54. Ryu HY, Mann KK, Schlezinger JJ, Jensen B, Sherr DH. Environmental chemical-induced pro/pre-B cell apoptosis: analysis of c-Myc, p27Kip1, and p21WAF1 reveals a death pathway distinct from clonal deletion. J Immunol. 2003 May 15; 170(10):4897-904. PMID: 12734332.
    View in: PubMed
  55. Takai Y, Canning J, Perez GI, Pru JK, Schlezinger JJ, Sherr DH, Kolesnick RN, Yuan J, Flavell RA, Korsmeyer SJ, Tilly JL. Bax, caspase-2, and caspase-3 are required for ovarian follicle loss caused by 4-vinylcyclohexene diepoxide exposure of female mice in vivo. Endocrinology. 2003 Jan; 144(1):69-74. PMID: 12488331.
    View in: PubMed
  56. Schlezinger JJ, Jensen BA, Mann KK, Ryu HY, Sherr DH. Peroxisome proliferator-activated receptor gamma-mediated NF-kappa B activation and apoptosis in pre-B cells. J Immunol. 2002 Dec 15; 169(12):6831-41. PMID: 12471115.
    View in: PubMed
  57. Matikainen TM, Moriyama T, Morita Y, Perez GI, Korsmeyer SJ, Sherr DH, Tilly JL. Ligand activation of the aromatic hydrocarbon receptor transcription factor drives Bax-dependent apoptosis in developing fetal ovarian germ cells. Endocrinology. 2002 Feb; 143(2):615-20. PMID: 11796517.
    View in: PubMed
  58. Matikainen T, Perez GI, Jurisicova A, Pru JK, Schlezinger JJ, Ryu HY, Laine J, Sakai T, Korsmeyer SJ, Casper RF, Sherr DH, Tilly JL. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. Nat Genet. 2001 Aug; 28(4):355-60. PMID: 11455387.
    View in: PubMed
  59. Mann KK, Doerre S, Schlezinger JJ, Sherr DH, Quadri S. The role of NF-kappaB as a survival factor in environmental chemical-induced pre-B cell apoptosis. Mol Pharmacol. 2001 Feb; 59(2):302-9. PMID: 11160867.
    View in: PubMed
  60. Kavanagh KT, Hafer LJ, Kim DW, Mann KK, Sherr DH, Rogers AE, Sonenshein GE. Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. J Cell Biochem. 2001; 82(3):387-98. PMID: 11500915.
    View in: PubMed
  61. Kim DW, Gazourian L, Quadri SA, Romieu-Mourez R, Sherr DH, Sonenshein GE. The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene. 2000 Nov 16; 19(48):5498-506. PMID: 11114727.
    View in: PubMed
  62. Jodo S, Hohlbaum AM, Xiao S, Chan D, Strehlow D, Sherr DH, Marshak-Rothstein A, Ju ST. CD95 (Fas) ligand-expressing vesicles display antibody-mediated, FcR-dependent enhancement of cytotoxicity. J Immunol. 2000 Nov 15; 165(10):5487-94. PMID: 11067901.
    View in: PubMed
  63. Quadri SA, Qadri AN, Hahn ME, Mann KK, Sherr DH. The bioflavonoid galangin blocks aryl hydrocarbon receptor activation and polycyclic aromatic hydrocarbon-induced pre-B cell apoptosis. Mol Pharmacol. 2000 Sep; 58(3):515-25. PMID: 10953044.
    View in: PubMed
  64. Trombino AF, Near RI, Matulka RA, Yang S, Hafer LJ, Toselli PA, Kim DW, Rogers AE, Sonenshein GE, Sherr DH. Expression of the aryl hydrocarbon receptor/transcription factor (AhR) and AhR-regulated CYP1 gene transcripts in a rat model of mammary tumorigenesis. Breast Cancer Res Treat. 2000 Sep; 63(2):117-31. PMID: 11097088.
    View in: PubMed
  65. Robles R, Morita Y, Mann KK, Perez GI, Yang S, Matikainen T, Sherr DH, Tilly JL. The aryl hydrocarbon receptor, a basic helix-loop-helix transcription factor of the PAS gene family, is required for normal ovarian germ cell dynamics in the mouse. Endocrinology. 2000 Jan; 141(1):450-3. PMID: 10614669.
    View in: PubMed
  66. Mann KK, Matulka RA, Hahn ME, Trombino AF, Lawrence BP, Kerkvliet NI, Sherr DH. The role of polycyclic aromatic hydrocarbon metabolism in dimethylbenz[a]anthracene-induced pre-B lymphocyte apoptosis. Toxicol Appl Pharmacol. 1999 Nov 15; 161(1):10-22. PMID: 10558919.
    View in: PubMed
  67. Near RI, Matulka RA, Mann KK, Gogate SU, Trombino AF, Sherr DH. Regulation of preB cell apoptosis by aryl hydrocarbon receptor/transcription factor-expressing stromal/adherent cells. Proc Soc Exp Biol Med. 1999 Jul; 221(3):242-52. PMID: 10404042.
    View in: PubMed
  68. Yamaguchi K, Matulka RA, Shneider AM, Toselli P, Trombino AF, Yang S, Hafer LJ, Mann KK, Tao XJ, Tilly JL, Near RI, Sherr DH. Induction of PreB cell apoptosis by 7,12-dimethylbenz[a]anthracene in long-term primary murine bone marrow cultures. Toxicol Appl Pharmacol. 1997 Dec; 147(2):190-203. PMID: 9439715.
    View in: PubMed
  69. Yamaguchi K, Near RI, Matulka RA, Shneider A, Toselli P, Trombino AF, Sherr DH. Activation of the aryl hydrocarbon receptor/transcription factor and bone marrow stromal cell-dependent preB cell apoptosis. J Immunol. 1997 Mar 1; 158(5):2165-73. PMID: 9036962.
    View in: PubMed
  70. Cui H, Ju ST, Sherr DH. Functional expression of Fas (CD95) protein in autoimmune lpr mice. Cell Immunol. 1996 Nov 25; 174(1):35-41. PMID: 8929452.
    View in: PubMed
  71. Vaziri C, Schneider A, Sherr DH, Faller DV. Expression of the aryl hydrocarbon receptor is regulated by serum and mitogenic growth factors in murine 3T3 fibroblasts. J Biol Chem. 1996 Oct 18; 271(42):25921-7. PMID: 8824226.
    View in: PubMed
  72. Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, FitzGerald MJ, Rothstein TL, Sherr DH, Sonenshein GE. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J. 1996 Sep 2; 15(17):4682-90. PMID: 8887559.
    View in: PubMed
  73. Wu M, Arsura M, Bellas RE, FitzGerald MJ, Lee H, Schauer SL, Sherr DH, Sonenshein GE. Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells. Mol Cell Biol. 1996 Sep; 16(9):5015-25. PMID: 8756660.
    View in: PubMed
  74. Yamaguchi K, Near R, Shneider A, Cui H, Ju ST, Sherr DH. Fluoranthene-induced apoptosis in murine T cell hybridomas is independent of the aromatic hydrocarbon receptor. Toxicol Appl Pharmacol. 1996 Jul; 139(1):144-52. PMID: 8685897.
    View in: PubMed
  75. Ting YL, Sherr D, Degani H. Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Anticancer Res. 1996 May-Jun; 16(3B):1381-8. PMID: 8694505.
    View in: PubMed
  76. Cui H, el-Khatib M, Sherr DH, Ettinger R, Sy MS, Marshak-Rothstein A, Ju ST. Characterization of lpr-derived T cell hybridomas: Fas-deficient hybridomas are deathless, growth-arrested, and cytotoxic upon activation. Cell Immunol. 1996 Feb 1; 167(2):302-12. PMID: 8603440.
    View in: PubMed
  77. Cui H, Sherr DH, el-Khatib M, Matsui K, Panka DJ, Marshak-Rothstein A, Ju ST. Regulation of T-cell death genes: selective inhibition of FasL- but not Fas-mediated function. Cell Immunol. 1996 Feb 1; 167(2):276-84. PMID: 8603437.
    View in: PubMed
  78. Hardin JA, Yamaguchi K, Sherr DH. The role of peritoneal stromal cells in the survival of sIgM+ peritoneal B lymphocyte populations. Cell Immunol. 1995 Mar; 161(1):50-60. PMID: 7867085.
    View in: PubMed
  79. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995 Feb 2; 373(6513):444-8. PMID: 7530337.
    View in: PubMed
  80. Peng B, Sherr DH, Mahboudi F, Hardin J, Wu YH, Sharer L, Raveché ES. A cultured malignant B-1 line serves as a model for Richter's syndrome. J Immunol. 1994 Aug 15; 153(4):1869-80. PMID: 8046247.
    View in: PubMed
  81. Hardin JA, Hinoshita F, Sherr DH. Mechanisms by which benzo[a]pyrene, an environmental carcinogen, suppresses B cell lymphopoiesis. Toxicol Appl Pharmacol. 1992 Dec; 117(2):155-64. PMID: 1335172.
    View in: PubMed
  82. Hardin JA, Sherr DH, DeMaria M, Lopez PA. A simple fluorescence method for surface antigen phenotyping of lymphocytes undergoing DNA fragmentation. J Immunol Methods. 1992 Sep 18; 154(1):99-107. PMID: 1401949.
    View in: PubMed
  83. Hardin JA, Gibson M, Grant E, Sherr DH. Interleukin 4 induces the maturation of idiotype-specific regulatory B cell populations. Proc Soc Exp Biol Med. 1992 Jul; 200(3):383-93. PMID: 1377393.
    View in: PubMed
  84. Hinoshita F, Hardin JA, Sherr DH. Fluoranthene induces programmed cell death and alters growth of immature B cell populations in bone marrow cultures. Toxicology. 1992; 73(2):203-18. PMID: 1609430.
    View in: PubMed
  85. Neugut AI, Sherr D, Robinson E, Murray T, Nieves J. Differences in histology between first and second primary lung cancer. Cancer Epidemiol Biomarkers Prev. 1992 Jan-Feb; 1(2):109-12. PMID: 1339080.
    View in: PubMed
  86. Hardin JA, Vos K, Kawano Y, Sherr DH. A function for Ly-1+ B cells. Proc Soc Exp Biol Med. 1990 Nov; 195(2):172-82. PMID: 2146687.
    View in: PubMed
  87. Hardin JA, Gibson M, Kawano Y, Spielberg S, Martin C, Collins M, Dorf ME, Sherr DH. Characterization of a B cell helper factor(s) derived from CD5+ B cell hybridomas. Cell Immunol. 1990 Apr 1; 126(2):304-21. PMID: 1690081.
    View in: PubMed
  88. Gibson M, Hardin JA, Sherr DH. A CD5+ B cell hybridoma derived factor(s), which induces maturation of CD5+, idiotype-specific B-cell populations. J Mol Cell Immunol. 1990; 4(5):241-51; discussion 251-3. PMID: 1698380.
    View in: PubMed
  89. O'Hara RM, Sherr DH, Dorf ME. In vitro generation of suppressor T cells. Induction of CD3+, IgH-restricted suppressor cells. J Immunol. 1988 Nov 1; 141(9):2935-42. PMID: 2459234.
    View in: PubMed
  90. O'Hara RM, Hausman PB, Sherr DH, Abromson-Leeman SR, Dorf ME. A role for L3T4+ T cells and their lymphokines in the generation of suppressor effector (TS3) cells. Cell Immunol. 1988 Oct 15; 116(2):423-38. PMID: 2972390.
    View in: PubMed
  91. Sherr DH, Dorf ME, Gibson M, Sidman CL. Ly-1 B helper cells in autoimmune "viable motheaten" mice. J Immunol. 1987 Sep 15; 139(6):1811-7. PMID: 2957439.
    View in: PubMed
  92. Sherr DH, Braun J, Dorf ME. Idiotype-specific Ly-1 B cell-mediated helper activity: hybridomas that produce anti-idiotype antibody and nonimmunoglobulin lymphokine(s)1. J Immunol. 1987 Apr 1; 138(7):2057-62. PMID: 3494058.
    View in: PubMed
  93. Hausman PB, Kawasaki H, O'Hara RM, Minami M, Sherr DH, Dorf ME. The role of adherent accessory cells in the generation of effector suppressor T cells. J Immunol. 1986 Dec 15; 137(12):3717-25. PMID: 2946768.
    View in: PubMed
  94. Sherr DH, Ju ST. Idiotype-specific helper cells (BH) express immunoglobulin markers and employ T cell function-associated molecules. J Immunol. 1986 Dec 1; 137(11):3406-13. PMID: 2946760.
    View in: PubMed
  95. Hausman PB, Sherr DH, Dorf ME. Anti-idiotypic B cells are required for the induction of suppressor T cells. J Immunol. 1986 Jan; 136(1):48-53. PMID: 2415628.
    View in: PubMed
  96. Hausman PB, Sherr DH, Dorf ME. Regulation of hapten-specific T and B cell responses by suppressor cells. Concepts Immunopathol. 1986; 3:38-60. PMID: 2954643.
    View in: PubMed
  97. Hausman PB, Sherr DH, Dorf ME. Mechanism controlling the genetic restrictions of an NP-specific suppressor factor that inhibits B cell responses. J Immunol. 1985 Aug; 135(2):915-21. PMID: 2409159.
    View in: PubMed
  98. Sherr DH, Dorf ME. H-2-restricted helper activity mediated by immunoglobulin-bearing lymphocytes. J Immunol. 1985 Apr; 134(4):2084-9. PMID: 3156178.
    View in: PubMed
  99. Hausman PB, Sherr DH, Dorf ME. An in vitro system for the generation of suppressor cells and the requirement for B cells in their induction. J Immunol. 1985 Mar; 134(3):1388-96. PMID: 2578504.
    View in: PubMed
  100. Sherr DH, Vietor HE, Liu YN, Dorf ME. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XIV. Carrier requirement for suppressor cell induction. J Immunol. 1984 Nov; 133(5):2417-22. PMID: 6207229.
    View in: PubMed
  101. Sherr DH, Dorf ME. Characterization of anti-idiotypic suppressor T cells (Tsid) induced after antigen priming. J Immunol. 1984 Sep; 133(3):1142-50. PMID: 6205068.
    View in: PubMed
  102. Sherr DH, Dorf ME. An idiotype-specific helper population that bears immunoglobulin, Ia, and Lyt-1 determinants. J Exp Med. 1984 Apr 1; 159(4):1189-200. PMID: 6200563.
    View in: PubMed
  103. Sherr DH, Minami M, Okuda K, Dorf ME. Analysis of T cell hybridomas. III. Distinctions between two types of hapten-specific suppressor factors that affect plaque-forming cell responses. J Exp Med. 1983 Feb 1; 157(2):515-29. PMID: 6185612.
    View in: PubMed
  104. Sherr DH, Dorf ME. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XIII. Characterization of a third T cell population involved in suppression of in vitro PFC responses. J Immunol. 1982 Mar; 128(3):1260-6. PMID: 6173430.
    View in: PubMed
  105. Sherr DH, Ju ST, Dorf ME. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XII. Fine specificity of anti-idiotypic suppressor T cells (Ts2). J Exp Med. 1981 Nov 1; 154(5):1382-9. PMID: 6170718.
    View in: PubMed
  106. Okuda K, Minami M, Sherr DH, Dorf ME. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XI. Pseudogenetic restrictions of hybridoma suppressor factors. J Exp Med. 1981 Aug 1; 154(2):468-79. PMID: 6167654.
    View in: PubMed
  107. Sherr DH, Dorf ME. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. IX. Characterization of Idiotype-specific effector-phase suppressor cells on plaque-forming cell responses in vitro. J Exp Med. 1981 Jun 1; 153(6):1445-56. PMID: 6454749.
    View in: PubMed
  108. Sherr DH, Huber BT, Gershon RK, Benacerraf B, Dorf ME. Effect of anti-Lyb3 antiserum on poly (L-glutamic acid, L-lysine)-induced B cell tolerance. Eur J Immunol. 1981 Mar; 11(3):241-6. PMID: 6165589.
    View in: PubMed
  109. Sherr DH, Ju ST, Weinberger JZ, Benacerraf B, Dorf ME. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. VII. Idiotype-specific suppression of plaque-forming cell responses. J Exp Med. 1981 Mar 1; 153(3):640-52. PMID: 7019373.
    View in: PubMed
  110. Sherr DH, Francus T, Szewczuk MR, Kim YT, Sogn D, Siskind GW. Ontogeny of B lymphocyte function. X. Strain differences in maturation of the capacity of the B lymphocyte population to produce a high-affinity antibody response. Eur J Immunol. 1981 Jan; 11(1):32-8. PMID: 6163636.
    View in: PubMed
  111. Sherr DH, Benacerraf B, Dorf ME. Immune suppression in vivo with antigen-modified syngeneic cells. V. Interacting T cell subpopulations in the suppressor pathway. J Immunol. 1980 Oct; 125(4):1862-8. PMID: 6997388.
    View in: PubMed
  112. Sherr DH, Heghinian KM, Benacerraf B, Dorf ME. Immune suppression in vivo with antigen-modified syngeneic cells. IV. Requirement for Ia+ adherent cells for induction. J Immunol. 1980 Mar; 124(3):1389-95. PMID: 6153681.
    View in: PubMed
  113. Sherr DH, Heghinian KM, Benacerraf B, Dorf ME. Immune suppression in vivo with antigen-modified syngeneic cells. III. Distinctions between T cell tolerance and T cell mediated suppression. J Immunol. 1979 Dec; 123(6):2682-8. PMID: 91641.
    View in: PubMed
  114. Sherr DH, Cheung NK, Heghinian KM, Benacerraf B, Dorf ME. Immune suppression in vivo with antigen-modified syngeneic cells. II. T cell-mediated nonresponsiveness to fowl gamma-globulin. J Immunol. 1979 May; 122(5):1899-904. PMID: 87447.
    View in: PubMed
  115. Sherr DH, Szewczuk MR, Cusano A, Rappaport W, Siskind GW. Ontogeny of B-lymphocyte function. IX. Difference in the time of maturation of the capacity of B lymphocytes from foetal and neonatal mice to produce a heterogeneous antibody response to thymic-dependent and thymic-independent antigens. Immunology. 1979 Apr; 36(4):891-907. PMID: 374264.
    View in: PubMed
  116. Szewczuk MR, Sherr DH, Cornacchia A, Kim YT, Siskind GW. Ontogeny of B lymphocyte function. XI. The secondary response by neonatal and adult B cell populations to different T-dependent antigens. J Immunol. 1979 Apr; 122(4):1294-301. PMID: 87429.
    View in: PubMed
  117. Szewczuk MR, Sherr DH, Siskind GW. Ontogeny of B lymphocyte function. VI. Ontogeny of thymus cell capacity to facilitate the functional maturation of B lymphocytes. Eur J Immunol. 1978 May; 8(5):370-3. PMID: 357163.
    View in: PubMed
  118. Sherr DH, Szewczuk MR, Siskind GW. Ontogeny of B-lymphocyte function. V. Thymus cell involvement in the functional maturation of B-lymphocytes from fetal mice transferred into adult irradiated hosts. J Exp Med. 1978 Jan 1; 147(1):196-206. PMID: 75233.
    View in: PubMed
  119. Sherr D, Szewczuk MR, Siskind GW. Ontogeny of B lymphocyte function. IV. Kinetics of maturation of B lymphocytes from fetal and neonatal mice when transferred into adult irradiated hosts. J Immunol. 1977 Nov; 119(5):1674-9. PMID: 334968.
    View in: PubMed
  120. Sherr DH, Siskind GW. Studies on the control of antibody synthesis. XI. Effect of antigen on the localization of cells secreting different avidity antibodies. Proc Soc Exp Biol Med. 1977 Jun; 155(2):203-8. PMID: 68477.
    View in: PubMed
David's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department